OncoMatch/Clinical Trials/NCT06247605
A Phase IIII Study of AL8326 in Small Cell Lung Cancer
Is NCT06247605 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies AL8326 tablets for small cell lung carcinoma.
Treatment: AL8326 tablets — This is a multicenter, randomized, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of AL8326 tablets in small cell lung cancer (SCLC) patients with disease progression or recurrence after receiving at least second-line treatment regimens.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Small Cell Lung Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: platinum-based chemotherapy — first-line
including first-line platinum-based therapy
Cannot have received: (AL8326)
Having previously used AL8326 tablets
Lab requirements
Blood counts
ANC ≥ 1.5 × 10^9/L (1500/mm3), platelets ≥ 80 × 10^9/L, hemoglobin ≥ 9.0 g/dL
Kidney function
Serum creatinine ≤ 1.5 × ULN and estimated creatinine clearance rate ≥ 60 ml/min by Cockcroft-Gault formula
Liver function
serum total bilirubin ≤ 1.5 × ULN (except Gilbert's syndrome); ALT and AST ≤ 2.5 × ULN (no liver mets), ≤ 5 × ULN (with liver mets)
Cardiac function
Left ventricular ejection fraction (LVEF) > 50% at screening
adequate organ and bone marrow function and meets the following laboratory criteria: ... see details above
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06247605 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages